Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Raloxifene|DRUG: Tamoxifen
Sponsor: NSABP Foundation Inc
Collaborators: National Cancer Institute (NCI)|Eli Lilly and Company|AstraZeneca